Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 33, Issue 1, 2014, Pages 73-80

  Halperin, Scott A ^a   Tapiéro, Bruce ^b   Dionne, Marc ^c   Meekison, William ^d   Diaz Mitoma, Francisco ^e   Zickler, Paul ^f   Rubin, Earl ^g   Embree, Joanne ^h   Bhuyan, Prakash ⁱ   Lee, Andrew ⁱ   Li, Minran ^j   Tomovici, Antigona ^j  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d Westcoast Clinical Research   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f TASC Research Services   (Canada)

^g MONTREAL CHILDREN S HOSPITAL   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j Sanofi Pasteur Limited   (Canada)

more..

Author keywords

Hexavalent Vaccine; Immunogenicity; Safety; Toddlers

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PNEUMOCOCCUS VACCINE; TETANUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BEHAVIOR DISORDER; BRONCHOSPASM; CHILD; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DROWSINESS; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FEBRILE CONVULSION; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATHOLOGICAL CRYING; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED;

EID: 84891532333     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/01.inf.0000437806.76221.20     Document Type: Article

References (22)

1. Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507-512
2. Halperin BA, Eastwood BJ, Halperin SA. Comparison of parental and health care professional preferences for the acellular or whole cell pertussis vaccine. Pediatr Infect Dis J. 1998;17:103-109
3. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J. 2001;20(11 suppl):S10-S18
4. Happe LE, Lunacsek OE, Marshall GS, et al. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506-512
5. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26: 496-500
6. Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: Experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22:300-309
7. Koslap-Petraco MB, Parsons T. Communicating the benefits of combination vaccines to parents and health care providers. J Pediatr Health Care. 2003;17:53-57
8. Dodd D. Benefits of combination vaccines: Effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 suppl):S6-12
9. Mullany L. Considerations for implementing a new combination vaccine into managed care. Am J Manag Care. 2003;9(1 suppl):S23-S29
10. E uropean Medicines Agency. Summary of opinion (initial authorisation); Bexsero: Meningococcal group B vaccine (rDNA, component, adsorbed). November 15, 2012. Available at: Http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/human/002333/ WC500134836.pdf. Accessed January 8, 2013
11. T apiéro B, Halperin SA, Dionne M, et al. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: A randomized, open-label study. Pediatr Infect Dis J. 2013;32:54-61
12. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010;28:5513-5523
13. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine. 2011;29:4881-4890
14. O rtega-Barrìa E, Kanra G, Leroux G, et al.; DTPw-HBV/Hib 2.5 study group. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: Results from four phase II multicenter trials across three continents. Vaccine. 2007;25:8432-8440
15. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J. 2000;19:1135-1140
16. C urran MP, Goa KL. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). Drugs. 2003;63:673-82; discussion 683
17. S chmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 2000;137:304-312
18. P oolman J, Kaufhold A, De Grave D, et al. Clinical releVance of lower Hib response in DTPa-based combination vaccines. Vaccine. 2001;19:2280-2285
19. Whelan J, Hahné S, Berbers G, et al. Immunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine. Findings from the National Immunisation Programme in The Netherlands. Hum Vaccin Immunother. 2012;8:743-748
20. Halperin SA, Langley JM, Hesley TM, et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussisinactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Hum Vaccin. 2005;1:245-250
21. Halperin SA, Tapiero B, Diaz-Mitoma F, et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine. 2009;27:2540-2547
22. Diaz-Mitoma F, Halperin SA, Tapiero B, et al. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus- acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. Vaccine. 2011;29:1324-1331